ADCY3 and ciliopathy: Indeed, modulation of cyclic AMP (cAMP) levels, the downstream product of AC3, in the treatment of renal ciliopathies has been widely studied with remarkable success and the V2 receptor antagonist tolvaptan is the only approved non-conservative treatment for the ciliopathy autosomal dominant polycystic kidney disease26.